{Reference Type}: Journal Article
{Title}: Evaluation of the Histone Deacetylase 2 (HDAC-2) Expression in Human Breast Cancer.
{Author}: Damaskos C;Psilopatis I;Garmpi A;Dimitroulis D;Nikolettos K;Vrettou K;Sarantis P;Koustas E;Kouraklis G;Antoniou EA;Karamouzis MV;Nikolettos N;Tsikouras P;Marinos G;Kontomanolis E;Kontzoglou K;Garmpis N;
{Journal}: Cancers (Basel)
{Volume}: 16
{Issue}: 1
{Year}: 2024 Jan 1
{Factor}: 6.575
{DOI}: 10.3390/cancers16010209
{Abstract}: <B>OBJECTIVE: </B>Triple negative breast cancer belongs to the most aggressive breast cancer forms. Histone deacetylases (HDACs) constitute a class of enzymes that exhibit a significant role in breast cancer genesis and progression. In this study, we aimed at assessing the clinical importance of HDAC-2 in triple negative breast cancer.<BR><B>METHODS: </B>A total of 138 breast cancer specimens were examined on an immunohistochemical basis. A statistical analysis was performed in order to examine the association between HDAC-2 and the survival and clinicopathological features of the patients.<BR><B>RESULTS: </B>Increased HDAC-2 expression was observed in every fourth case of triple negative breast cancer with positive HDAC-2 staining, whereas only 12 out of 98 non-triple negative breast cancer samples showed high HDAC-2 expression. HDAC-2 overexpression correlated with prolonged overall survival (OS) and disease-free survival (DFS) in triple negative breast cancer.<BR><B>CONCLUSIONS: </B>High HDAC-2 levels in triple negative breast cancer seem to positively influence patient survival, disease stage and recurrence.